| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,607 |
6,978 |
$1.68M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,682 |
2,672 |
$730K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,740 |
1,445 |
$588K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,596 |
4,697 |
$583K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,656 |
1,267 |
$349K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,158 |
3,743 |
$216K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,392 |
2,710 |
$212K |
| G0378 |
Hospital observation service, per hour |
551 |
379 |
$165K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
554 |
485 |
$145K |
| 71046 |
Radiologic examination, chest; 2 views |
2,949 |
2,306 |
$140K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,632 |
2,136 |
$133K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,140 |
1,358 |
$131K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
496 |
461 |
$130K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,306 |
2,309 |
$128K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,542 |
2,587 |
$121K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
156 |
126 |
$120K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,521 |
1,553 |
$119K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,876 |
2,754 |
$91K |
| 76830 |
Ultrasound, transvaginal |
380 |
328 |
$81K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
373 |
211 |
$76K |
| 80053 |
Comprehensive metabolic panel |
14,580 |
10,242 |
$76K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
382 |
343 |
$74K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,164 |
849 |
$66K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
16,515 |
11,433 |
$63K |
| 71045 |
Radiologic examination, chest; single view |
2,075 |
1,535 |
$50K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
681 |
615 |
$49K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
141 |
108 |
$49K |
| 59025 |
Fetal non-stress test |
506 |
271 |
$45K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,081 |
3,497 |
$38K |
| 36415 |
Collection of venous blood by venipuncture |
17,636 |
12,662 |
$36K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,081 |
1,998 |
$35K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
494 |
460 |
$34K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,406 |
771 |
$34K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
589 |
468 |
$32K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
974 |
716 |
$31K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
214 |
111 |
$30K |
| 73630 |
|
441 |
326 |
$27K |
| 76801 |
|
91 |
68 |
$23K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
110 |
92 |
$23K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
891 |
297 |
$23K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
3,980 |
2,764 |
$22K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,297 |
1,087 |
$22K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,523 |
1,019 |
$21K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
950 |
834 |
$21K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
953 |
836 |
$21K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,846 |
2,347 |
$20K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,266 |
2,008 |
$18K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
925 |
846 |
$18K |
| 80061 |
Lipid panel |
1,991 |
1,843 |
$17K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,953 |
2,764 |
$16K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
49 |
40 |
$15K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,009 |
1,556 |
$15K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
323 |
257 |
$15K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,850 |
3,089 |
$14K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,300 |
2,738 |
$14K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
566 |
498 |
$13K |
| 84484 |
|
3,752 |
2,053 |
$13K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
102 |
83 |
$12K |
| 80306 |
|
1,145 |
902 |
$9K |
| 87070 |
|
1,414 |
1,233 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
964 |
838 |
$9K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
50 |
38 |
$9K |
| 83690 |
|
2,498 |
1,952 |
$9K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
285 |
227 |
$9K |
| 85027 |
|
2,480 |
1,835 |
$9K |
| 83735 |
|
3,147 |
2,121 |
$8K |
| 84703 |
|
1,479 |
1,254 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
356 |
276 |
$8K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
309 |
83 |
$7K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
37 |
27 |
$7K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,777 |
1,489 |
$7K |
| 86140 |
|
2,634 |
2,062 |
$7K |
| 71250 |
|
15 |
14 |
$7K |
| 96376 |
|
172 |
141 |
$7K |
| 97161 |
|
98 |
79 |
$6K |
| 81001 |
|
4,219 |
3,318 |
$6K |
| 73502 |
|
139 |
108 |
$6K |
| 94762 |
|
365 |
275 |
$6K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
2,461 |
1,642 |
$6K |
| 87040 |
|
1,201 |
768 |
$6K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
348 |
251 |
$6K |
| 73560 |
|
109 |
87 |
$6K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,199 |
1,045 |
$5K |
| 73030 |
|
104 |
80 |
$5K |
| 87077 |
|
1,226 |
1,019 |
$5K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
321 |
236 |
$5K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
214 |
163 |
$5K |
| 83880 |
|
532 |
353 |
$5K |
| 86850 |
|
720 |
598 |
$5K |
| 85610 |
|
2,978 |
1,737 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
563 |
281 |
$5K |
| 87481 |
|
309 |
124 |
$5K |
| 73610 |
|
75 |
65 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,207 |
858 |
$4K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
14 |
12 |
$4K |
| 87186 |
|
871 |
709 |
$4K |
| 83605 |
|
1,127 |
778 |
$4K |
| 82728 |
|
410 |
344 |
$4K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
187 |
156 |
$4K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
23 |
15 |
$4K |
| 87511 |
|
210 |
163 |
$4K |
| 87400 |
|
381 |
304 |
$4K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
65 |
58 |
$3K |
| 84702 |
|
260 |
200 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,857 |
2,102 |
$3K |
| 82607 |
|
364 |
313 |
$3K |
| 86803 |
|
287 |
257 |
$3K |
| 72100 |
|
40 |
37 |
$3K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
119 |
88 |
$2K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
12 |
12 |
$2K |
| 81003 |
|
1,918 |
1,564 |
$2K |
| 86780 |
|
209 |
170 |
$2K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
21 |
12 |
$2K |
| 84439 |
|
295 |
264 |
$2K |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
128 |
100 |
$2K |
| J3490 |
Unclassified drugs |
569 |
284 |
$2K |
| 82746 |
|
128 |
110 |
$2K |
| 82948 |
|
1,565 |
463 |
$2K |
| 83550 |
|
287 |
229 |
$2K |
| 86901 |
|
723 |
584 |
$2K |
| 86900 |
|
704 |
570 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
792 |
639 |
$1K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
220 |
131 |
$1K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
78 |
42 |
$1K |
| 87340 |
|
160 |
141 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
245 |
174 |
$1K |
| 83540 |
|
308 |
246 |
$1K |
| 87081 |
|
262 |
236 |
$1K |
| 85651 |
|
557 |
430 |
$1K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
294 |
232 |
$1K |
| 85380 |
|
134 |
112 |
$1K |
| 81025 |
|
261 |
190 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
351 |
207 |
$935.82 |
| J2704 |
Injection, propofol, 10 mg |
81 |
61 |
$934.26 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
808 |
655 |
$916.96 |
| 73130 |
|
17 |
13 |
$901.30 |
| 93000 |
|
15 |
12 |
$890.80 |
| 85730 |
|
376 |
279 |
$890.46 |
| 87653 |
|
34 |
27 |
$839.41 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
78 |
63 |
$810.60 |
| 83655 |
|
66 |
54 |
$726.28 |
| 73140 |
|
15 |
12 |
$679.49 |
| 86762 |
|
59 |
53 |
$671.61 |
| 86618 |
|
57 |
54 |
$667.77 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
18 |
16 |
$616.36 |
| 90715 |
|
14 |
12 |
$603.97 |
| 11721 |
|
242 |
88 |
$549.76 |
| 73110 |
|
17 |
12 |
$535.26 |
| 87205 |
|
153 |
125 |
$417.39 |
| 82962 |
|
306 |
135 |
$391.35 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
110 |
99 |
$382.53 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
307 |
120 |
$363.70 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
17 |
12 |
$314.18 |
| 80320 |
|
16 |
13 |
$310.50 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
33 |
14 |
$195.30 |
| 82950 |
|
45 |
39 |
$191.95 |
| 88142 |
|
12 |
12 |
$187.30 |
| J2060 |
Injection, lorazepam, 2 mg |
70 |
51 |
$149.18 |
| 99215 |
Prolong outpt/office vis |
20 |
12 |
$134.05 |
| 81002 |
|
132 |
89 |
$123.90 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
14 |
12 |
$97.21 |
| 80050 |
General health panel |
12 |
12 |
$92.76 |
| 11720 |
|
44 |
12 |
$82.55 |
| 85652 |
|
37 |
31 |
$80.40 |
| 99307 |
|
35 |
16 |
$77.25 |
| 84550 |
|
15 |
12 |
$50.24 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
47 |
37 |
$49.73 |
| 84100 |
|
14 |
12 |
$36.38 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
37 |
35 |
$21.65 |
| A9270 |
Non-covered item or service |
16 |
13 |
$6.29 |
| Q0247 |
Injection, sotrovimab, 500 mg |
23 |
15 |
$0.22 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
888 |
654 |
$0.03 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
12 |
12 |
$0.02 |